Subtopic Deep Dive
VEGF in Hypertrophic Osteoarthropathy
Research Guide
What is VEGF in Hypertrophic Osteoarthropathy?
VEGF in hypertrophic osteoarthropathy examines the role of vascular endothelial growth factor in driving periostosis, pachydermia, and hypervascularization associated with HOA manifestations.
Studies measure elevated serum VEGF levels in HOA patients and demonstrate symptom relief with VEGF inhibition using octreotide (Maroto et al., 2005, 63 citations). Research links VEGF to digital clubbing via hypervascularization observed in high-resolution MRI (Nakamura et al., 2014, 19 citations). Approximately 10 papers from 2005-2023 explore VEGF pathways in primary and secondary HOA.
Why It Matters
Elevated VEGF serves as a biomarker for HOA severity, enabling non-invasive monitoring of periostosis progression (Maroto et al., 2005). Anti-angiogenic therapies targeting VEGF, such as octreotide, resolve painful bone symptoms in clinical cases, offering treatment options beyond symptom management (Maroto et al., 2005). In paraneoplastic HOA linked to thyroid cancer, VEGF inhibition addresses underlying vascular drivers (Tavarelli et al., 2015). These pathways support precision medicine approaches in rheumatology for pachydermoperiostosis.
Key Research Challenges
Linking VEGF to Periostosis
Research struggles to causally connect serum VEGF elevations to bone formation in HOA due to confounding factors like underlying lung pathology (Maroto et al., 2005). Few studies quantify VEGF gradients at periosteal sites. Longitudinal trials are absent.
VEGF Inhibition Specificity
Octreotide reduces VEGF but lacks HOA-specific trials, risking off-target effects (Maroto et al., 2005). Differentiating VEGF responses in primary vs. secondary HOA remains unclear (Lu et al., 2023). Dose-response data for anti-VEGF agents is limited.
Biomarker Validation
Serum VEGF levels correlate with symptoms but require validation against imaging endpoints like MRI hypervascularity (Nakamura et al., 2014). Standardization across HOA subtypes is needed. Few papers assess VEGF in pediatric or genetic cases (Limenis et al., 2021).
Essential Papers
Painful hypertrophic osteoarthropathy successfully treated with octreotide. The pathogenetic role of vascular endothelial growth factor (VEGF)
Alicia Maroto, Efrén Martínez‐Quintana, Laura Suárez-Castellano et al. · 2005 · Lara D. Veeken · 63 citations
Primary hypertrophic osteoarthropathy: genetics, clinical features and management
Qi Lu, Yang Xu, Zeng Zhang et al. · 2023 · Frontiers in Endocrinology · 37 citations
Primary hypertrophic osteoarthropathy (PHO) is a genetic disorder mainly characterized by clubbing fingers, pachydermia and periostosis. Mutations in the HPGD or SLCO2A1 gene lead to impaired prost...
Lost bones: differential diagnosis of acro-osteolysis seen by the pediatric rheumatologist
Elizaveta Limenis, Jennifer Stimec, Pekka Kannus et al. · 2021 · Pediatric Rheumatology · 21 citations
Abstract Introduction Acro-osteolysis is a radiographic finding which refers to bone resorption of the distal phalanges. Acro-osteolysis is associated with various conditions and its presence shoul...
The Microanatomic Basis of Finger Clubbing — A High-resolution Magnetic Resonance Imaging Study
Junichi Nakamura, Nicola Ann Halliday, Eiji Fukuba et al. · 2014 · The Journal of Rheumatology · 19 citations
Objective. Hypervascularization in finger clubbing is recognized, but its microanatomical basis remains unclear. This pilot descriptive study used magnetic resonance imaging (MRI) to explore this f...
Hypertrophic Osteopathy Secondary to Nodular Pulmonary Fibrosis in a Horse
Joy E. Tomlinson, T. J. Divers, Sean P. McDonough et al. · 2010 · Journal of Veterinary Internal Medicine · 17 citations
A 5-year-old, 515-kg, Thoroughbred-Warmblood cross gelding was referred to the Cornell University Hospital for Animals for evaluation of hard swellings on the long bones of the limbs and intermitte...
Touraine-Soulente-Golé Syndrome: A Rare Case Report and Review of the Literature
Sumir Kumar, Sandeep Singh Sidhu, Bharat Bhushan Mahajan · 2013 · Annals of Dermatology · 15 citations
Touraine-Soulente-Golé Syndrome (TSG) or pachydermoperiostosis is a rare disorder characterized by pachydermia, periostosis & digital clubbing. Herein, we report a case of a 27 year old male, with ...
Myelofibrosis Successfully Treated with Prednisolone in a Patient with Pachydermoperiostosis
Soranobu Ninomiya, Takeshi Hara, Hisashi Tsurumi et al. · 2011 · Internal Medicine · 15 citations
Pachydermoperiostosis (PDP) is a rare disorder of bone and connective tissue growth. A 21-year-old man was referred to our hospital with anemia. He showed characteristics of PDP. Bone marrow biopsy...
Reading Guide
Foundational Papers
Start with Maroto et al. (2005, 63 citations) for core VEGF-octreotide evidence in painful HOA; follow with Nakamura et al. (2014, 19 citations) for MRI-based vascular mechanisms in clubbing.
Recent Advances
Lu et al. (2023, 37 citations) integrates VEGF with PHO genetics; Tavarelli et al. (2015) covers paraneoplastic HOA.
Core Methods
Serum VEGF ELISA (Maroto et al., 2005); high-resolution MRI for microanatomy (Nakamura et al., 2014); genetic sequencing for HPGD/SLCO2A1 in context (Lu et al., 2023).
How PapersFlow Helps You Research VEGF in Hypertrophic Osteoarthropathy
Discover & Search
Research Agent uses searchPapers('VEGF hypertrophic osteoarthropathy') to retrieve Maroto et al. (2005) as top result with 63 citations, then citationGraph reveals forward citations in paraneoplastic HOA like Tavarelli et al. (2015). findSimilarPapers expands to VEGF in pachydermoperiostosis cases (Kumar et al., 2013). exaSearch uncovers rare veterinary models (Tomlinson et al., 2010).
Analyze & Verify
Analysis Agent applies readPaperContent on Maroto et al. (2005) to extract VEGF serum levels pre/post-octreotide, then verifyResponse with CoVe cross-checks claims against Nakamura et al. (2014) MRI data for consistency. runPythonAnalysis processes citation metadata in pandas to plot VEGF paper trends over time, with GRADE grading evidence as moderate due to case-report designs.
Synthesize & Write
Synthesis Agent detects gaps in VEGF trial data across HOA subtypes via gap detection, then flags contradictions between primary genetic models (Lu et al., 2023) and secondary cases. Writing Agent uses latexEditText to draft VEGF pathway reviews, latexSyncCitations for 10-paper bibliographies, and latexCompile for publication-ready sections with exportMermaid diagrams of VEGF-octreotide mechanisms.
Use Cases
"Extract and plot serum VEGF levels from HOA treatment papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas plot of Maroto et al. 2005 levels) → matplotlib figure exported as PNG.
"Write LaTeX review of VEGF inhibition in HOA"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Maroto 2005, Nakamura 2014) → latexCompile → PDF output.
"Find code for VEGF quantification in HOA imaging"
Research Agent → paperExtractUrls (Nakamura 2014 MRI methods) → paperFindGithubRepo → githubRepoInspect → Python scripts for vascular density analysis.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ HOA papers, chaining searchPapers → citationGraph → GRADE grading, producing VEGF biomarker report with Maroto et al. (2005) as anchor. DeepScan applies 7-step analysis with CoVe checkpoints to verify octreotide efficacy claims from case reports. Theorizer generates hypotheses linking VEGF to HPGD mutations in PHO (Lu et al., 2023).
Frequently Asked Questions
What defines VEGF's role in HOA?
VEGF drives hypervascularization and periostosis in HOA, with elevated serum levels correlating to symptom severity (Maroto et al., 2005).
What methods study VEGF in HOA?
Serum ELISA quantifies VEGF; high-resolution MRI visualizes clubbing vascularity; octreotide tests inhibition (Maroto et al., 2005; Nakamura et al., 2014).
What are key papers on VEGF in HOA?
Maroto et al. (2005, 63 citations) shows octreotide success; Nakamura et al. (2014, 19 citations) links to MRI hypervascularity.
What open problems exist?
Lack of randomized VEGF inhibition trials; unclear VEGF role in primary genetic HOA; need for periosteal VEGF localization (Lu et al., 2023).
Research Hypertrophic osteoarthropathy and related conditions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching VEGF in Hypertrophic Osteoarthropathy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers